Damora Therapeutics, Inc. - Ordinary Shares (DMRA)
23.70
+1.84 (8.42%)
NASDAQ · Last Trade: Nov 7th, 6:01 PM EST
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surgefool.com
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
Via The Motley Fool · May 30, 2026